Effect of Dutasteride and Imidafenacin in BPH/OAB patients not respond to eight weeks'continuous treatment of Tamsulosin.

Trial Profile

Effect of Dutasteride and Imidafenacin in BPH/OAB patients not respond to eight weeks'continuous treatment of Tamsulosin.

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2016

At a glance

  • Drugs Imidafenacin (Primary) ; Dutasteride
  • Indications Benign prostatic hyperplasia; Overactive bladder
  • Focus Therapeutic Use
  • Acronyms DIrecT
  • Sponsors Kyorin Pharmaceutical
  • Most Recent Events

    • 16 Sep 2016 Results of subgroup analysis (n=163) presented at the 46th Annual Meeting of the International Continence Society.
    • 07 Apr 2016 Status changed from active, no longer recruiting to completed.
    • 15 Oct 2014 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan .
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top